The remarkable acceleration observed in the development of treatments for rare neurodegenerative disorders marks a monumental epoch in medical history. Once relegated to the periphery of pharmaceutical interest due to small patient numbers and complex pathophysiology, this market segment is now central to R&D pipelines globally. The paradigm shift is attributable to a confluence of...